University of Leeds

Richard James Foster

Mark Richard Stewart

Alan Naylor

Philip Spencer Fallon

Natalie Louise Winfield

Anna Hopkins

David John Beech

Roger Taylor

Lucie Juliette Guetzoyan

Stuart Crosby

Alistair James Macnair

Colin Fishwick

Baptiste Michel Rode

Helen Philippou

Sin Ying Cheung

Charlotte Revill

Ian Yule

This invention relates to compounds of formula (I) and methods of treatment using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. The compounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.

Factor XIIA inhibitors

Described herein are inhibitors Transient Receptor Potential Canonical (TRPC) ion channels comprising TRPC4 protein and/or TRPC5 protein for use in combating obesity and other medical conditions including insulin resistance associated with Type II diabetes or development of Type II diabetes (pre-diabetes), metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Also disclosed is the use of the inhibitors for cosmetic purposes, such as cosmetic weight loss.

TRPC ion channel inhibitors for use in therapy

Growing community of inventors

Leeds, United Kingdom

Richard James Foster